Abstract
In an industry rife with failures, Proteolix, a biotechnology company, was a rare success. The Proteolix case provides a compelling example of a biotech company that has chosen a “me-too” strategy, a less risky strategy than the strategy of discovering a drug for a novel target. However, even me-too drug strategies in the biotech industry face an uphill battle.
Get full access to this article
View all access options for this article.